Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/-mice-role of intestinal permeability and macrophage activation

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Ghosh, Siddhartha S ^a   Bie, Jinghua ^a   Wang, Jing ^a   Ghosh, Shobha ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CLAUDIN 1; CURCUMIN; DRINKING WATER; FATTY ACID; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; NEOMYCIN PLUS POLYMYXIN B; PROTEIN ZO1; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CONTROLLED STUDY; DIET; DISEASE EXACERBATION; DRUG EFFICACY; ENZYME ACTIVITY; GLUCOSE INTOLERANCE; IN VIVO STUDY; INTESTINAL BARRIER; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MACROPHAGE ACTIVATION; MEDICAL PROCEDURES; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SELECTIVE GUT DECONTAMINATION; SUPPLEMENTATION; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; GENETICS; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ATHEROSCLEROSIS; CURCUMIN; DIET, WESTERN; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MICE; MICE, KNOCKOUT; NF-KAPPA B; RECEPTORS, LDL;

EID: 84907587722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108577     Document Type: Article

References (37)

1. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, et al. (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature. 505: 559-63.
2. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, et al. (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 19: 576-585.
3. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, et al (2014) Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 63: 116-124.
4. Pendyala S, Walker JM, Holt PR (2012) A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142: 1100-1101. e2.
5. Sandek A, Anker SD, von Haehling S (2009) The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab. 10: 2-28.
6. Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Wensel R, et al. (2002) Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 90: 1226-1230.
7. Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, et al. (2013) Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 37: 518-525.
8. Bengmark S (2013) Gut microbiota, immune development and function. Pharmacol Res. 69: 87-113.
9. González-Hernández LA, Jave-Suarez LF, Fafutis-Morris M, Montes-Salcedo KE, Valle-Gutierrez LG, et al. (2012) Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIVinfected patients: a double-blind randomized controlled pilot trial. Nutr J. 11: 90.
10. Montenegro L, Losurdo G, Licinio R, Zamparella M, Giorgio F, et al. (2014) Non-Steroidal Anti-Inflammatory Drug Induced Damage On Lower Gastro-Intestinal Tract: Is There A Involvement Of Microbiota? Curr Drug Saf. Apr 24. (Epub ahead of print)
11. Lee HJ, Zhang H, Orlovich DA, Fawcett JP (2012) The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 42: 791-797.
12. Guiot HF and van Furth R (1992) Selective decontamination in bone marrow transplant recipients. Epidemiol Infect. 109: 349-360.
13. Midura-Kiela MT, Radhakrishnan VM, Larmonier CB, Laubitz D, Ghishan FK (2012) Curcumin inhibits interferon-c signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G85-96.
14. Yao Q, Ye X, Wang L, Gu J, Fu T, et al. (2013) Protective effect of curcumin on chemotherapy-induced intestinal dysfunction. Int J Clin Exp Pathol. 6: 2342-2349.
15. Wang N, Wang G, Hao J, Ma J, Wang Y, et al. (2012) Curcumin ameliorates hydrogen peroxide-induced epithelial barrier disruption by upregulating heme oxygenase-1 expression in human intestinal epithelial cells. Dig Dis Sci. 57: 1792-1801.
16. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC (2010) Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010; 299: G440-448.
17. Bie J, Wang J, Yuan Q, Kakiyama G, Ghosh SS, et al. (2014) Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr2/2 mice. J Lipid Res. 55: 729-738.
18. Miles JM, Woolridge D, Grellner WJ, Windsor S, Isley WL, et al. (2003) Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy.Diabetes. 52: 675-681.
19. Narisawa S, Huang L, Iwasaki A, Hasegawa H, Alpers DH et al.(2003)Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol 23: 7525-7530.
20. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, et al. (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 101: 10679-10684.
21. OConnor C, Dunne MW, Pfeffer MA, Muhlestein JB, Investigators in the WIZARD Study, et al. (2003) Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 290: 1459-66.
22. Groschwitz KR, Hogan SP (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 124: 3-20.
23. Suzuki T, Tanabe S, Hara H (2011) Kaempferol enhances intestinal barrier function through the cytoskeletal association and expression of tight junction proteins in Caco-2 cells. J Nutr. 141: 87-94.
24. Keita AV, Söderholm JD (2010) The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil. 22: 718-733.
25. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, et al. (2002) Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock. 18: 561-566.
26. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, et al. (2009) Role of alkaline phosphatase in colitis in man and rats. Gut 58: 379-387.
27. Kiffer-Moreira T, Sheen CR, Gasque KC, Bolean M, Ciancaglini P, et al. (2014) Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential. PLoS One. 9: e89374.
28. Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, et al. (2009) Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol. 296: F1146-1157.
29. Ghosh SS, Krieg R, Massey HD, Sica DA, Fakhry I, et al. (2012) Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. Am J Physiol Renal Physiol. 302: F439-454.
30. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
31. Maitra U, Gan L, Chang S, Li L (2011) Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein d. J Immunol. 186: 4467-4473.
32. Deng H, Maitra U, Morris M, Li L (2013) Molecular mechanism responsible for the priming of macrophage activation. J Biol Chem. 288:3897-3906.
33. Maradana MR, Thomas R, OSullivan BJ (2013) Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res. 57: 1550-1556.
34. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, et al. (2014) Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis. 232: 40-51.
35. Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, et al. (2012) Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res. 56: 1270-1281.
36. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al. (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 14: 4491-9.
37. Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, et al. (2013) Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration-a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila). 6: 119-28.